Leaps by Bayer leads Robigo's Series A for engineered microbial biopesticides
Leaps by Bayer leads Robigo's Series A for an engineered microbe applied on the seed that produces its own crop protection all season.
Robigo, a crop protection company based in Cambridge, Massachusetts, announced a Series A financing on 17 September 2026. Leaps by Bayer led the round. Illumina Ventures, SVG Thrive, Congruent Ventures and Endeavor8 also took part. The size of the round was not disclosed. Robigo was founded by Dr Andee Wallace, who is chief executive.
The product is a seed treatment built on engineered microbes rather than wild-type strains. The company's ARGO platform combines microbial strain engineering, strain selection and computational design of the active ingredient, which works by silencing genes in the target pathogen. AgNavigator describes the platform as drawing on RNA interference and CRISPR. Applied once at planting, the microbe produces the active ingredient through the growing season and requires no cold-chain storage.
The first product targets Sudden Death Syndrome in soybeans, with launch targeted for 2028. A second, aimed at Fusarium wilt in lettuce and berries, is targeted for 2029. Robigo puts the addressable market for soil-borne pathogens in broadacre crops at around $10 billion. AgNavigator reports that the platform compresses development from an industry-standard three to five years to under 20 months.
“Growers shouldn't have to choose between a product that works and one that's affordable,” said Wallace. Dr Juergen Eckhardt, who heads Leaps by Bayer, framed the investment around the platform rather than the first product: “They are not just developing a single product but rather building an engine that can rapidly address diverse soil-borne pathogens.” The proceeds go to the commercial launch in the United States and to widening the pipeline to further soil-borne pathogens.
Why it matters for AgTech founders: two things here are worth copying and one is worth watching. The first is the delivery choice. Robigo is not asking a grower to add a field pass, buy a machine or hold stock in a cold room; it rides the seed treatment step that already exists. Biologicals have more often died on application logistics and shelf life than on efficacy, and removing the cold chain removes a distributor conversation that kills deals quietly. The second is the framing that won the lead. Leaps by Bayer bought a platform and a pipeline, not a soybean product, and the pitch was clearly built that way. The thing to watch is the clock: a 2028 launch for a live engineered microbe means the regulatory path, not the biology, sets the schedule, and a European founder building the same thing should assume a slower route than the US one Robigo is on and size the raise to survive it. Note too that the amount is undisclosed, so treat it as a data gap rather than a signal when benchmarking your own round.
Leaps by Bayer leads Robigo's Series A for engineered microbial biopesticides
The Cambridge, Massachusetts company puts an engineered microbe on the seed and lets it make the active ingredient all season. Round size undisclosed; first product targeted for 2028.
Robigo, a crop protection company based in Cambridge, Massachusetts, announced a Series A financing on 17 September 2026. Leaps by Bayer led the round. Illumina Ventures, SVG Thrive, Congruent Ventures and Endeavor8 also took part. The size of the round was not disclosed. Robigo was founded by Dr Andee Wallace, who is chief executive.
The product is a seed treatment built on engineered microbes rather than wild-type strains. The company's ARGO platform combines microbial strain engineering, strain selection and computational design of the active ingredient, which works by silencing genes in the target pathogen. AgNavigator describes the platform as drawing on RNA interference and CRISPR. Applied once at planting, the microbe produces the active ingredient through the growing season and requires no cold-chain storage.
The first product targets Sudden Death Syndrome in soybeans, with launch targeted for 2028. A second, aimed at Fusarium wilt in lettuce and berries, is targeted for 2029. Robigo puts the addressable market for soil-borne pathogens in broadacre crops at around $10 billion. AgNavigator reports that the platform compresses development from an industry-standard three to five years to under 20 months.
“Growers shouldn't have to choose between a product that works and one that's affordable,” said Wallace. Dr Juergen Eckhardt, who heads Leaps by Bayer, framed the investment around the platform rather than the first product: “They are not just developing a single product but rather building an engine that can rapidly address diverse soil-borne pathogens.” The proceeds go to the commercial launch in the United States and to widening the pipeline to further soil-borne pathogens.
Why it matters for AgTech founders: two things here are worth copying and one is worth watching. The first is the delivery choice. Robigo is not asking a grower to add a field pass, buy a machine or hold stock in a cold room; it rides the seed treatment step that already exists. Biologicals have more often died on application logistics and shelf life than on efficacy, and removing the cold chain removes a distributor conversation that kills deals quietly. The second is the framing that won the lead. Leaps by Bayer bought a platform and a pipeline, not a soybean product, and the pitch was clearly built that way. The thing to watch is the clock: a 2028 launch for a live engineered microbe means the regulatory path, not the biology, sets the schedule, and a European founder building the same thing should assume a slower route than the US one Robigo is on and size the raise to survive it. Note too that the amount is undisclosed, so treat it as a data gap rather than a signal when benchmarking your own round.
